> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Voyager Cuts Research Spending To $24.4 Million, Extends Funding Outlook Into 2028
- URL: https://www.bullished.co/voyager-cuts-research-spending-to-24-4-million-extends-funding-outlook-into-2028-ec1dad46/
- Published: 2026-11-06T17:10:57.000Z
- Updated: 2026-11-06T17:10:57.000Z
- Description: The biotech expects Alzheimer’s imaging results in the fourth quarter and first gene-therapy dosing in the coming months, pending enrollment.
- Author: Matteo Parrino
- Tags: Earnings, VYGR, Industry: Healthcare

[Voyager Therapeutics](https://www.bullished.co/tag/vygr/), which develops genetic medicines for neurological diseases, cut third-quarter research spending to [$24.4 million](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co) and now expects funding to cover its operating plans into the second quarter of 2028\. The company announced its results Thursday in an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-20261105.htm?ref=bullished.co), with Alzheimer’s trial imaging results expected in the fourth quarter.

## Lower Costs, Lower Partner Revenue

Research and development spending was $35.9 million in the year-earlier quarter. Voyager attributed the reduction to program prioritization and lower costs for clinical work and manufacturing; administrative spending also fell, to $6.1 million from $8.1 million, as employee-related expenses and consulting costs declined.

Collaboration revenue fell to $4.0 million from $13.4 million a year earlier. Voyager said the main reason was that work under its Neurocrine Biosciences agreement was moving beyond the research phase. The quarterly net loss narrowed to $24.7 million from $27.9 million, or $0.40 per share versus $0.47.

Partner reimbursements appear on both sides of Voyager’s accounts—as revenue and research expenses. Excluding those reimbursements, its adjusted net research spending was $20.969 million, compared with $33.654 million a year earlier; adjusted net collaboration revenue was $612,000, versus $11.153 million.

Voyager held $132.1 million in cash, cash equivalents and marketable securities on September 30, 2026\. Its funding outlook includes anticipated collaboration reimbursements and interest income alongside those holdings, and rests on current operating plans.

## Two Alzheimer’s Programs Approach Readouts

Voyager has completed the last patient visit in the trial of VY7523, its antibody aimed at the tau protein. Imaging results expected in the fourth quarter will measure its effect on tau in participants with Alzheimer’s disease.

The other lead Alzheimer’s candidate, VY1706, is a gene therapy designed to silence tau. Screening is continuing in the United States among adults with early Alzheimer’s disease, and dosing remains dependent on enrollment.

Alfred W. Sandrock, Jr., Voyager’s chief executive officer, said the company expects “to dose the [first patient](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co) with our lead gene therapy VY1706 in the next few months.” Initial acute safety results are expected in the first quarter of 2027\. Initial tau biomarker results from cerebrospinal fluid could become available approximately one year after dosing begins, potentially providing evidence for the company’s capsid platform.

Neurocrine expects its partnered Friedreich’s ataxia gene-therapy program to start an early-stage clinical trial in the coming months. Initial patient-level results are anticipated in 2027.

## Partner Funding And A CEO Transition

Voyager develops some medicines independently and others with partners, including Neurocrine, Novartis, Alexion and Transition Bio. Its broader pipeline also targets Parkinson’s disease and other central nervous system disorders.

Many programs originate from TRACER, Voyager’s platform for finding viral capsids—the protein shells that carry gene therapies—designed to reach the brain after intravenous dosing. Partner fees, milestone payments and research reimbursements help finance that work; its partnerships have provided more than $500.0 million in funding without issuing shares.

The clinical schedule also coincides with a planned leadership handover. Robin Swartz was appointed president in October 2026 and is expected to succeed Sandrock as CEO.

VYGR shares rose about 6% to $1.82 in Friday trading.

The nearest expected clinical result is VY7523’s fourth-quarter tau imaging readout; VY1706’s initial safety results are expected in the first quarter of 2027.

Learn

- [Item 2.01: completion of an acquisition or disposition →](https://www.bullished.co/learn/8-k-items-explained/#item-201-completion-of-an-acquisition-or-disposition)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Voyager Therapeutics, Inc. (VYGR)](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit vygr-ex99\_1.htm — Voyager Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001640266/000119312526449728/vygr-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Voyager Reports Third Quarter 2026 Financial and Operating](https://www.globenewswire.com/news-release/2026/11/05/3397004/0/en/voyager-reports-third-quarter-2026-financial-and-operating-results.html?ref=bullished.co) — globenewswire.com

### More on Voyager Therapeutics

- [Voyager Therapeutics Names Robin Swartz President, Expects Her To Succeed CEO Alfred Sandrock](https://www.bullished.co/voyager-therapeutics-names-robin-swartz-president-expects-her-to-succeed-ceo-alfred-814a98c9/)

[All Voyager Therapeutics (VYGR) coverage →](https://www.bullished.co/tag/vygr/)